Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.61 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.61 |
| ▸ | FABP3 | P05413 | 6/20 | 0.62 |
| ▸ | TERT | O14746 | 3/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.61 |
| ▸ | PPARG | P37231 | 3/20 | 0.61 |
| ▸ | PPARD | Q03181 | 3/20 | 0.61 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | FABP4 | P15090 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | F7 | P08709 | 2/20 | 0.61 |
| ▸ | F3 | P13726 | 2/20 | 0.61 |
| ▸ | GMNN | O75496 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25963 | 1.00 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL35815 | 1.00 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| SCHEMBL7045888 | 0.98 | FABP3 (0.65) | FABP3TERTPTPN1PPARGPPARD | |
| SCHEMBL4133929 | 0.98 | FABP3 (0.65) | FABP3TERTPTPN1PPARGPPARD | |
| SCHEMBL1626315 | 0.98 | FABP3 (0.65) | FABP3TERTPTPN1PPARGPPARD | |
| Water SCHEMBL3915284 | 0.96 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Water SCHEMBL3915280 | 0.96 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Propane SCHEMBL480215 | 0.96 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Bromide SCHEMBL3414482 | 0.96 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Iodide SCHEMBL6695071 | 0.96 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | JENKEM TECH CO LTD BEIJING (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | HDT BIO CORP (US) | 2026-02-12 | — | — | US | claimed |
| EP-4342929-B1 | POLYETHYLENE GLYCOL LIPID AND USE THEREOF | JENKEM TECH CO LTD TIANJIN (CN) | 2026-02-04 | — | — | EP | claimed |
| US-20260007769-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | HDT BIO CORP (US) | 2026-01-08 | — | — | US | claimed |
| US-12485163-B2 | Cancer therapy compositions and uses thereof | HDT BIO CORP. (US) | 2025-12-02 | — | — | US | claimed |
| US-20250313844-A1 | INTERFERING RNA FOR INHIBITING PCSK9 GENE EXPRESSION AND USE THEREOF | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2025-10-09 | — | — | US | claimed |
| US-12433957-B2 | Compositions and methods for delivery of RNA | HDT BIO CORP. (US) | 2025-10-07 | — | — | US | claimed |
| US-20250295751-A1 | RNA VACCINES AGAINST INFECTIOUS DISEASES | HDT BIO CORP. | 2025-09-25 | — | — | US | claimed |
| US-20250228930-A1 | SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE | HDT BIO CORP. | 2025-07-17 | — | — | US | claimed |
| EP-4583841-A1 | IMMUNOGENIC VACCINE COMPOSITION INCORPORATING A SAPONIN | Access to Advanced Health Institute (US) | 2025-07-16 | — | — | EP | claimed |
| US-9655845-B2 | Oil-in-water emulsions that contain nucleic acids | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2017-05-23 | — | — | US | claimed |
| US-9636410-B2 | Cationic oil-in-water emulsions | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-05-02 | — | — | US | claimed |
| US-20160256541-A1 | Cationic Oil-In-Water Emulsions | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-09-08 | — | — | US | claimed |
| US-9295646-B2 | Cationic oil-in-water emulsions | NOVARTIS AG (CH) | 2016-03-29 | — | — | US | claimed |
| US-20140220083-A1 | CATIONIC OIL-IN-WATER EMULSIONS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2014-08-07 | — | — | US | claimed |
| US-20140212498-A1 | OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2014-07-31 | — | — | US | claimed |
| US-20120156251-A1 | CATIONIC OIL-IN-WATER EMULSIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-06-21 | — | — | US | claimed |
| US-20080118500-A1 | Nanosphere contains phospholipid/cholesterol particle comprising vesicle, and agent-carrying component capable of forming complex with therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; cyclodextrins | TAIWAN LIPOSOME COMPANY (TW) | 2008-05-22 | — | — | US | claimed |
| US-20070275048-A1 | LIPOSOME COMPOSITION FOR DELIVERY OF A THERAPEUTIC AGENT TO EYES | TAIWAN LIPOSOME CO. LTD. (TW) | 2007-11-29 | — | — | US | claimed |
| WO-2000009071-A2 | A NOVEL LIPOSOMAL FORMULATION USEFUL IN TREATMENT OF CANCER AND OTHER PROLIFERATION DISEASES | ALL INDIA INSTITUTE OF MEDICAL SCIENCES (IN) | 2000-02-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | TOP1, TOP2A, TOP2B | CHRM1 3643/4885SLC6A2 852/4885FABP3 1346/4885 |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | ITGAL, ITGA2B, ITGA2 | CHRM1 93/4885SLC6A2 3035/4885FABP3 558/4885 |
| US-20260007769-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | PLTP, FLNA, NSUN2 | CHRM1 3009/4885SLC6A2 1503/4885FABP3 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.